Anacalypsis Therapeutics (ATx)
Company websiteHardy J. Rideout
Chief Scientific Officer, Co-Founder; Anacalypsis Therapeutics, IKE
hrideout at anacalypsistherapeutics.com; hrideout08 at gmail.com
75 Leof. Thessalonikis, 18345 Moschato (Athens), Greece
ORCID: 0000-0003-4597-9489
Google Scholar
Hardy Rideout earned his PhD degree in Anatomy & Neurobiology (Neuroscience) in 2001 from Dalhousie University in Halifax, Canada. Following the completion of is doctoral research work, he began post-doctoral training in the laboratiory of Dr. Leonidas Stefanis in the Dept of Neurology at Columbia University. In 2004, he joined the lab of Dr. William Dauer, also at Columbia University in the role of Associate Research Scientist, until 2008. In 2009, Dr. Rideout joined the Biomedical Research Foundation of the Academy of Athens as Group Leader (LRRK2) in the Neurodegenerative Diseases Research Labs.
In 2019, he co-founded, as the Chief Scientific Officer (CSO), Anacalypsis Therapeutics (ATx), a private company based in Athens Greece. The focus of the R & D of ATx is the discovery and development of novel disease modifying therapeutics and biomarker tools for neurodegenerative diseases such as Parkinson's Disease (PD), Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS). Gene and pathway-based analyses underscore the therapeutic target identification, and cellular as well as in vivo pre-clinical models are employed.
His academic work, prior to the founding of Anacalypsis Therapeutics, focussed on neuronal death mechanisms in familial as well as idiopathic forms of PD; identifying a key cell death pathway that is triggered by mutant forms of proteins linked to PD, and advancing the characterization of LRRK2 dimerization in the regulation of LRRK2 kinase activity.